Form 8-K MACROGENICS INC For: Apr 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Stifel on MacroGenics (MGNX): 'incrementally more positive', 'We remain buyers into the next “by May 31” clinical update'
April 4, 2024 4:40 AM EDTStifel analyst Stephen Willey reiterated a Buy rating and $29.00 price target on MacroGenics (NASDAQ: MGNX).
The analyst comments "Were incrementally more positive on MGNX shares following managements disclosure of vobra-duo safety/tolerability data from the P2 TAMARACK trial contained within an... More
